Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technolog…
The business is unprofitable at the operating level (-2345.99% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 58.9% YoY with margins expanding 2840.2pp.
Negative free cash flow of -$19M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$3M
▲ +58.9% YoY
Net Income (TTM)
-$24M
▲ +1.1% YoY
Op. Margin
-1092.96%
▲ +2840.2pp YoY
ROIC
-100.56%
▲ +25.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$17M
▲ +47.4% YoY
Op. Cash Flow (TTM)
-$17M
▲ +47.3% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$10M
5Y CAGR: +28.7%
Continue Research